Rafael Holdings Reports Q2 Results, Phase 3 Study Continues with DMC Recommendation

summarizeSummary

Rafael Holdings reported increased Q2 losses driven by an acquisition, but highlighted positive progress in its pivotal Phase 3 clinical trial for Niemann-Pick Disease Type C1, with the Data Monitoring Committee recommending continuation.

check_boxKey Events

• Q2 Fiscal 2026 Financial Results

  Reported a net loss of $6.4 million ($0.13 per share) for the quarter ended January 31, 2026, an increase from $4.6 million in the prior year, primarily due to the Cyclo Therapeutic acquisition.

• Phase 3 Clinical Trial Progress

  The Data Monitoring Committee (DMC) recommended continuing the pivotal Phase 3 TransportNPC™ study for Niemann-Pick Disease Type C1 after reviewing 48-week safety and efficacy data.

• Top-Line Results Expected

  Preliminary top-line results from the 96-week Phase 3 clinical trial are anticipated in the third quarter of calendar year 2026.

• Cash Position

  The company held $37.8 million in cash and cash equivalents as of January 31, 2026, providing operational runway.

auto_awesomeAnalysis

Rafael Holdings reported an increased net loss for the second fiscal quarter of 2026, primarily attributed to the consolidation of expenses following the acquisition of Cyclo Therapeutic in March 2025. Despite the financial loss, the company provided a significant positive update on its pivotal Phase 3 TransportNPC™ study for Niemann-Pick Disease Type C1. The Data Monitoring Committee (DMC) recommended continuing the study after reviewing prespecified safety and efficacy data, which de-risks the trial. Preliminary top-line results are expected in the third quarter of calendar year 2026, representing a major upcoming catalyst for the company. The company's cash position of $37.8 million as of January 31, 2026, provides approximately 15 months of operational runway at current burn rates.